Regeneron Pharmaceuticals, Inc.

Tammy T Huang

Joel H Martin

Nicholas J Papadopoulos

Jeanette L Fairhurst

Ashique Rafique

Gang Chen

Sean Stevens

Kevin J Pobursky

Eric L Smith

Margaret Karow

James P Fandl

Douglas MacDonald

Mark W Sleeman

Andrew J Murphy

George D Yancopoulos

Neil E Stahl

Robert Babb

William C Olson

Christos Kyratsous

Alina Baum

Wen-Yi Lee

Ergang Shi

Cindy Gerson

Johanna Hansen

Marine Malbec

Allen Radin

Joan A Windsor

Warren R Mikulka

Diana M Ahrens

Marcela Torres

Raymond W Leidich

Gary Swergold

Lynn Macdonald

Eric B Smith

Lori C Morton

Mark Sleeman

Robert C Pordy

William J Sasiela

Michael E Dunn

Vishal Kamat

Ishita Chatterjee

Wen-yi Lee

Douglas Macdonald

Eric Smith

The present disclosure provides novel immunoglobulin proteins that bind to a human natriuretic peptide receptor 1 (NPR1) agonist, preferably an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure comprise at least one immunoglobulin variable domain that binds to an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure are useful in blocking and/or reversing the effect of an administered anti-NPR1 antibody. In certain embodiments, the antigen-binding proteins are useful for effective management of blood pressure and hemodynamics in humans.

Immunoglobulin proteins that bind to NPR1 agonists

An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period relative to predose levels, with little or no reduction in serum HDL cholesterol and/or with little or no measurable effect on liver function, as determined by ALT and AST measurements.

Anti-PCSK9 antibodies

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).

Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

The present invention provides nucleic acid molecules that encode antibodies or antigen-binding fragments thereof, which specifically bind human interleukin-4 receptor (IL-4R). Also provided are expression vectors comprising nucleic acid molecule that encode anti-IL-4R antibodies, host cells comprising the expression vectors, and methods of producing anti-IL-4R antibodies or antigen-binding fragments thereof comprising growing the host cells under conditions permitting production of the antibody or fragment, and recovering the antibody or fragment so produced.

High affinity human antibodies to human IL-4 receptor

A human antibody or an antigen-binding fragment which binds human IL-6 receptor (hIL-6R) with a Kof about 500 pM or less and blocks IL-6 activity with an ICof 200 pM or less, is provided. In preferred embodiments, the antibody the antibody or antigen-binding fragment binds hIL-6R with an affinity at least 2-fold higher relative to its binding monkey IL-6R.

High affinity antibodies to human IL-6 receptor

Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments

Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.

Vantigen binding proteins exhibiting distinct binding characteristics

Nucleic acids encoding high affinity antibodies to human IL-6 receptor

The present invention provides methods for treating hypercholesterolemia and reducing LDL-C. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an anti-PCSK9 antibody or antigen-binding fragment thereof.

Methods for treating hypercholesterolemia and reducing LDL-C using antibodies to PCSK9

Growing community of inventors

Goldens Bridge, NY, United States of America

Tammy T Huang